The AI-based clinical trial solution providers market is rapidly growing, expected to expand from $3.03 billion in 2025 to $3.72 billion in 2026, and reach $8.53 billion by 2030 with a 23% CAGR. Growth is fueled by AI advancements optimizing patient recruitment, trial predictions, and real-time monitoring, alongside cloud-based and decentralized trial platforms. Key players like IBM and Saama Technologies are innovating with AI-driven data platforms, while regions like North America lead the market and Asia Pacific shows fastest growth. This market transformation enhances clinical trial accuracy and efficiency, especially in oncology and cardiovascular research.
Energy prices cooled in June, easing inflation pressures despite ongoing tensions between the U.S. and Iran near the Strait of Hormuz. Morgan Stanley reported record quarterly revenue and profit, boosted by a surge in equities trading fueled by the A...
IBM reported earnings and revenue below expectations due to enterprises reducing spending on traditional IT systems to invest in their own AI infrastructure. This shift indicates companies prefer developing on-premises AI solutions with cheaper open-...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
IBM introduced Power Autonomous Operations, an AI agent that autonomously monitors and resolves issues in Power systems up to 15 times faster than manual methods, enhancing system uptime and efficiency. Alongside, IBM launched the Power S1112, a comp...
Sperax, creator of the auto-yield stablecoin USDs and SperaxOS AI agent workspace, has become an official IBM Business Partner. This partnership combines Sperax's AI-driven DeFi technology with IBM's enterprise AI and cloud infrastructure, enabling r...
